SMALL CELL LUNG CÁNCER . NUEVA TERAPIA DE PRECISIÓN : La Predicción Clínica del Beneficio de la QUIMIOTERAPIA Y la QUIMIORRADIOTERAPIA Basadas en PLATINO ... Podría Convertirse en una Nueva Estrategia Personalizada .

 

TRATAMIENTOS ACTUALES SMALL CELL LUNG CANCER CON QUIMIOTERAPIA :

PLATINOS / ETOPOSIDE .

TRATAMIENTOS ACTUALES CON INMUNOTERAPIAS :

*.- DURVALUMAB BY ASTRAZÉNECA : OVERALL SURVIVAL DE 12.9 MESES .

*.- ATEZOLIZUMAB BY ROCHE : OVERALL SURVIVAL DE 12,3 MESES .

*.- SERPLULIMAB BY Shanghai Henlius ( Aprobado Ya en EUROPA , CHINA , INDIA ... ) :  CONSIGUE UNA OVERALL SURVIVAL DE 15,4 MESES .

*.-TORIPALIMAB ( Aprobado Ya en CHINA ）: CONSIGUE UNA OVERALL SURVIVAL DE 14,6 MESES .

*****************

***********

*******

Clinical Combined PET/CT Radiomics Model Prediction of Benefit From PLATINUM-BASED CHEMOTHERAPY And CHEMORADIOTHERAPY In Patients With SMALL CELL LUNG CÁNCER  .

Objective 

To develop and validate a clinical combined radiomics model for predicting the treatment response and long-term survival prognosis of small cell lung cancer (SCLC) patients receiving platinum-based chemotherapy, as well as survival outcomes following chemoradiotherapy .

Methods 

A total of 98 SCLC patients treated with platinum-based first-line chemotherapy were included in this study. Five prediction models for assessing the short-term efficacy of platinum-based first-line chemotherapy were developed using a logistic regression algorithm. The performance of the models was assessed by calculating the area under the curve of the receiver operating characteristic curves. For predicting progression-free survival (PFS) and overall survival in the platinum-based chemotherapy group and the chemoradiotherapy group, the optimal cutoff value was determined using X-tile software. Kaplan–Meier survival curves were plotted, and the log-rank test was used to compare survival outcomes .

Results 

Among the five models for predicting short-term efficacy, the clinical combined positron emission tomography/computed tomography (PET/CT) radiomics model performed the best, achieving areas under the curve of 0.832 and 0.833 for the training and test sets, respectively. The Kaplan–Meier survival analysis indicated that both the high-scoring Combine group and high-scoring PET/CT group were significantly associated with worse PFS and worse overall survival in the platinum-only chemotherapy group. Additionally, the high-scoring CT group was significantly associated with worse PFS in the chemoradiotherapy group. 

Conclusion 

The clinical combined PET/CT radiomics model can noninvasively and accurately predict the response to platinum-based treatments in SCLC as well as long-term survival prognosis, which can contribute to personalized treatment strategies and guide precision therapy for SCLC patients .